Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 9;13:1079566. doi: 10.3389/fphar.2022.1079566

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Huang, Zhao, Zhang, Zhao, Zhang, Chen and Dai.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

CLST and aCD4 were involved in drug sensitivity to anti-HBV immunotherapy and anti-cancer chemotherapies. (A) Comparisons of CLST and aCD4 between PEG IFN-α treatment responders and non-responders (GSE27555). (B) Heatmaps showing differences in liver samples from HBV-infected patients pre and post PEG-IFN-α treatment (GSE66698). (C) Boxplot of pairwise comparisons of CLST, aCD4, NKT, and MDSC between the control group and PEG IFN-α-treated group (GSE66698). (D) Correlations among CLST, aCD4, NKT, and MDSC in PEG IFN-α-treated liver samples (GSE66698). (E) Volcano plot of the sensitivity of HBV-HCC patients in the CLST^highaCD4^high subgroup and CLST^lowaCD4^low subgroup to 198 anti-cancer drugs. (F) Comparisons of the sensitivity to first-line chemotherapy (sorafenib) and emerging chemotherapies (SB505124, dihydrorotenone) between the CLST^highaCD4^high subgroup and CLST^lowaCD4^low subgroup (CHCC).